BridgeMD
New treatment option for Interstitial Lung Disease
Official title Impact of Capillaroscopy in the Investigation of Diffuse Interstitial Pneumonias
ClinicalTrials.gov ID: NCT07283081
What this study is testing
- What it's testing
- The investigators hypothesize that in patients with a new diagnosis of Pulmonary Interstitial Disease (PID), adding capillaroscopy to standard care increases the proportion of patients receiving a diagnosis of PID-Connective Tissue Disease (PID-CTD) within the first three months of follow-up, thereby reducing the time to diagnosis and facilitating the implementation of appropriate treatment as quickly as possible. Therefore, To confirm this hypothesis, it is necessary to know the characteristics of capillaroscopy in patients with a new diagnosis of PID.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Male or female over 18 years of age;
- Have received a new diagnosis of PID within the last six months, confirmed by a pulmonologist;
- Have undergone some specific tests within the last six months (Chest CT scan, respiratory function tests (plethysmography and CO transfer capacity...
- French-speaking patient with no comprehension difficulties;
- Person affiliated with or beneficiary of a social security system;
You likely can't join if
- Have previously undergone a capillaroscopy, regardless of the reason;
- Have a diagnosis or high suspicion of connective tissue disease based on initial clinical and paraclinical evaluation;
- Have already started one of the following treatments for pulmonary involvement: systemic corticosteroids, immunosuppressive therapy, antifibrotic...
- Pregnant or breastfeeding women;
- Patients covered by Articles L 1121-5 to L 1121-8 (persons deprived of their liberty by judicial or administrative decision, minors, adults subject...
See the full eligibility criteria
- Male or female over 18 years of age;
- Have received a new diagnosis of PID within the last six months, confirmed by a pulmonologist;
- Have undergone some specific tests within the last six months (Chest CT scan, respiratory function tests (plethysmography and CO transfer capacity measurement, immunological assessment including: screening for FAN, FR...
- French-speaking patient with no comprehension difficulties;
- Person affiliated with or beneficiary of a social security system;
- Free, informed, and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research).
- Have previously undergone a capillaroscopy, regardless of the reason;
- Have a diagnosis or high suspicion of connective tissue disease based on initial clinical and paraclinical evaluation;
- Have already started one of the following treatments for pulmonary involvement: systemic corticosteroids, immunosuppressive therapy, antifibrotic therapy;
- Pregnant or breastfeeding women;
- Patients covered by Articles L 1121-5 to L 1121-8 (persons deprived of their liberty by judicial or administrative decision, minors, adults subject to legal protection measures, or persons unable to give their consent).
The study team makes the final eligibility decision.
Where it's taking place
- Bordeaux, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bordeaux, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.